First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
June 27, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.